Αποτελέσματα Αναζήτησης
10 Ιουλ 2024 · New HIV drug can only offer hope of ending AIDS if all have access, UNAIDS says. GENEVA, 10 July 2024— UNAIDS has welcomed the release of Gilead Sciences’ trial results on the injectable long-acting HIV medicine Lenacapavir for HIV prevention.
4 Ιαν 2023 · Sunlenca (lenacapavir) is a new type of antiretroviral medication for HIV-1 patients who have resistance, intolerance, or safety issues with other drugs. It is the first capsid inhibitor approved by the FDA and is given as oral tablets and subcutaneous injections every six months.
12 Σεπ 2024 · Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly.
27 Ιαν 2021 · FDA approved CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use. This is the first...
23 Δεκ 2021 · The Food and Drug Administration has approved a new drug in the fight against AIDS. It's the first injectable medication for HIV prevention. NPR's global health correspondent Jason Beaubien...
10 Ιαν 2023 · The FDA has approved Gilead Science’s first-in-class capsid inhibitor lenacapavir, providing a new treatment option for people with multidrug-resistant HIV.
23 Δεκ 2021 · Apretude, a new drug approved by the FDA this week, is an injection that has proven to be significantly more effective at reducing the risk of sexually-acquired HIV.
